Cerenis Therapeutics, a France and US-based biopharmaceutical company, has made a second close of its series C at €10m ($14m) to take the round to €50m and its overall total equity to €117m.
The €10m came from the French investment company IRDI, which is managed by local venture capital firm IXO, with both investing €2.5m, and undisclosed international private investors.
In July, Cerenis made its first close at €40m with French state-backed Strategic Investment Fund investing €20m. The remainder came from Cerenis’ previous backers: Daiwa Corporate Investment, the corporate venturing division of Japan-based bank Daiwa, and VCs Sofinnova Partners, HealthCap, Alta Partners, TVM Capital, EDF Ventures and OrbiMed.